Novartis And The Medicines Company: Five Things To Worry About

 
• By Bridget Silverman

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

Close metal silver hinge is mounted on the glass construction of the door to the sauna, bathroom or shower cubicle against the background of the wooden floor
The Novartis-Medicines Company merger hinges on the commercial potential of a single product.

More from Market Access

More from Pink Sheet